WallStSmart

AstraZeneca PLC (AZN)vsBrainsway Ltd (BWAY)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 102683% more annual revenue ($62.38B vs $60.70M). AZN leads profitability with a 17.7% profit margin vs 15.6%. AZN trades at a lower P/E of 26.8x. AZN earns a higher WallStSmart Score of 68/100 (B-).

AZN

Strong Buy

68

out of 100

Grade: B-

Growth: 6.7Profit: 8.5Value: 6.0Quality: 5.5
Piotroski: 6/9Altman Z: 1.48

BWAY

Buy

51

out of 100

Grade: C-

Growth: 10.0Profit: 6.5Value: 4.7Quality: 7.5
Piotroski: 5/9Altman Z: 1.40
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+4.3%)

Margin of Safety

+4.3%

Fair Value

$197.94

Current Price

$184.45

$13.49 discount

UndervaluedFair: $197.94Overvalued

Intrinsic value data unavailable for BWAY.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN5 strengths · Avg: 8.6/10
Market CapQuality
$293.73B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
21.3%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
29.6%8/10

Strong operational efficiency at 29.6%

EPS GrowthGrowth
23.5%8/10

Earnings expanding 23.5% YoY

Free Cash FlowQuality
$3.99B8/10

Generating 4.0B in free cash flow

BWAY3 strengths · Avg: 10.0/10
Revenue GrowthGrowth
35.4%10/10

Revenue surging 35.4% year-over-year

EPS GrowthGrowth
59.8%10/10

Earnings expanding 59.8% YoY

Debt/EquityHealth
0.0910/10

Conservative balance sheet, low leverage

Areas to Watch

AZN2 concerns · Avg: 3.0/10
P/E RatioValuation
26.8x4/10

Moderate valuation

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

BWAY3 concerns · Avg: 2.3/10
Market CapQuality
$406.96M3/10

Smaller company, higher risk/reward

P/E RatioValuation
42.1x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.402/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 29.6%. PEG of 1.35 suggests the stock is reasonably priced for its growth.

Bull Case : BWAY

The strongest argument for BWAY centers on Revenue Growth, EPS Growth, Debt/Equity. Profitability is solid with margins at 15.6% and operating margin at 12.5%. Revenue growth of 35.4% demonstrates continued momentum.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, Altman Z-Score.

Bear Case : BWAY

The primary concerns for BWAY are Market Cap, P/E Ratio, Altman Z-Score. A P/E of 42.1x leaves little room for execution misses.

Key Dynamics to Monitor

AZN profiles as a mature stock while BWAY is a growth play — different risk/reward profiles.

AZN carries more volatility with a beta of 0.15 — expect wider price swings.

BWAY is growing revenue faster at 35.4% — sustainability is the question.

AZN generates stronger free cash flow (4.0B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (68/100 vs 51/100), backed by strong 17.7% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Brainsway Ltd

HEALTHCARE · MEDICAL DEVICES · USA

Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.

Want to dig deeper into these stocks?